Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In this Phase 2 trial, 32 heavily pretreated patients including those who received adjuvant temozolamide, were treated with daily low-dose temozolamide at 50 mg/m2 and twice-weekly Bevacizumab. The treatment was well tolerated with a median progression-free survival of 15.8 weeks and a median overall survival of 37 weeks. However, this was lower than those reported in studies with single-agent bevacizumab and bevacizumab/irinotecan combination.

Combination Treatment with Low-Dose Protracted Temozoloamide and Bevacizumab for Heavily Pretreated Patients with Recurrent Glioblastoma